Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

Team

Borbas, Dave

Dave Borbas

Research VP,
Head of Data Management

x

Dave Borbas

Research VP,
Head of Data Management

Byrne, Donna

Donna Byrne

Director, Clinical Operations

x

Donna Byrne

Director, Clinical Operations

Chartienitz, Brett

Brett Chartienitz

IT Operations Manager

x

Brett Chartienitz

IT Operations Manager

Cooper, Ken

Ken Cooper

Director Clinical Operations, Trial Management

x

Ken Cooper

Director Clinical Operations, Trial Management

Greenberg, Steven A.

Steven A Greenberg, M.D., M.S. is a founder of Abcuro and the Chief Scientific Advisor. Steve is a clinical neurologist at Brigham and Women’s Hospital, and Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion body myositis, and therapeutics,

 READ MORE

Steven A. Greenberg, MD

Chief Scientific Advisor & Co-Founder

x

Steven A. Greenberg, MD

Chief Scientific Advisor & Co-Founder

Steven A Greenberg, M.D., M.S. is a founder of Abcuro and the Chief Scientific Advisor. Steve is a clinical neurologist at Brigham and Women’s Hospital, and Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion body myositis, and therapeutics, including co-inventing a therapeutic monoclonal antibody for dermatomyositis currently in late-stage clinical trials. He has authored over 100 publications and served as Principal Investigator for multiple clinical trials. Steve received an A.B. degree in Mathematics from Princeton University, an M.S. degree in Medical Informatics from Massachusetts Institute of Technology, and an M.D. degree from Harvard Medical School through the Harvard-MIT Health Science and Technology Program.

Gress, Mike

Mike Gress

VP, Clinical Development,
Head of Clinical Trial Management

x

Mike Gress

VP, Clinical Development,
Head of Clinical Trial Management

Hwang, Ella

Ella Hwang

Vice President, Quality

x

Ella Hwang

Vice President, Quality

LeMessurier, Hugo

Hugo LeMessurier

Director, Abcuro Pty Ltd

x

Hugo LeMessurier

Director, Abcuro Pty Ltd

Luk, Jeffrey

Jeffrey Luk

Senior Director, Head of Manufacturing

x

Jeffrey Luk

Senior Director, Head of Manufacturing

Mansuri, Daniel

Daniel Mansuri

Head of Corporate Development

x

Daniel Mansuri

Head of Corporate Development

Martin, Alex

Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA

 READ MORE

Alex Martin, MBA

Chief Executive Officer

x

Alex Martin, MBA

Chief Executive Officer

Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA Pharma (EPIX). He was also Chief Operating Officer of Intercept Pharmaceuticals (ICPT), and Chief Finance Officer of BioXell (BXLN) which was acquired by Cosmo Pharmaceuticals (COPN). He began his career at SmithKline Beecham Pharmaceuticals where he held roles of increasing responsibility in marketing and business development and later joined Novartis as Vice President, Global Business Development & Licensing. Alex is an active coach and mentor to other senior executives, and a guest lecturer at Wharton and Columbia Business School on biotech, entrepreneurship, and raising capital. He holds a BA from Cornell University and an MBA from Harvard.

Morgan, Shelly

Shelly Morgan

Senior Director, Regulatory Affairs

x

Shelly Morgan

Senior Director, Regulatory Affairs

Motschwiller, Ricky

Richard Motschwiller

VP, Finance

x

Richard Motschwiller

VP, Finance

Reyes, Armando

Armando Reyes

Director, Clinical Operations

x

Armando Reyes

Director, Clinical Operations

Shen, Yuyi

Yuyi Shen, PhD

VP, Technical Operations

x

Yuyi Shen, PhD

VP, Technical Operations

Srinivasan, Usha

Usha Srinivasan

Vice President, Regulatory Affairs

x

Usha Srinivasan

Vice President, Regulatory Affairs

Sundaram, Sam

Sam Sundaram

Executive Assistant & Operations Manager

x

Sam Sundaram

Executive Assistant & Operations Manager

Tubridy, Karen

Karen Tubridy is the Chief Operating Officer of Abcuro.  She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics. Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio. She has had responsibility for driving global program strategies to IND,

 READ MORE

Karen Tubridy, PharmD

Chief Operating Officer

x

Karen Tubridy, PharmD

Chief Operating Officer

Karen Tubridy is the Chief Operating Officer of Abcuro.  She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics. Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio. She has had responsibility for driving global program strategies to IND, NDA and J-NDA filings. In addition, she has had responsibility for oversight of drug development operations including the build out of core R&D infrastructure and quality systems. Previously, she held senior positions in clinical and regulatory operations at Inspiration Biopharmaceuticals, Taligen Therapeutics (acquired by Alexion) and Syntonix Pharmaceuticals (acquired by Biogen). She held a senior position at AVANT Immunotherapeutics directing several vaccine programs and held positions of increasing responsibility in clinical research and medical affairs at Genetics Institute/Wyeth Pharmaceuticals, where she directed hematology and oncology programs. Karen holds a BS in pharmacy and a PharmD from the Massachusetts College of Pharmacy and Allied Health Sciences.

Weems Gary

Garry Weems

VP, Clinical Science

x

Garry Weems

VP, Clinical Science

Wilkins, Jeffrey

Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among

 READ MORE

H. Jeffrey Wilkins, MD

Chief Medical Officer

x

H. Jeffrey Wilkins, MD

Chief Medical Officer

Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among others, Jeff led clinical development programs at Avalo Therapeutics, Lycera, Ceptaris Therapeutics, Cephalon, and Ception Therapeutics. He entered the pharmaceutical industry with GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. Jeff received his MD from Temple University School of Medicine and his BS from Bucknell University.

Privacy Site Credits Terms of Use

© 2026 Abcuro